[1]肖正芳,郑游冰,邓飞燕,等.基于TACE联合治疗原发性肝细胞癌的研究进展[J].介入放射学杂志,2024,33(06):688-692.
　XIAO Zhengfang,ZHENG Youbing,DENG Feiyan,et al.Research progress in TACE-based combination therapy for primary hepatocellular carcinoma[J].journal interventional radiology,2024,33(06):688-692.
点击复制

基于TACE联合治疗原发性肝细胞癌的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年06
页码:
688-692
栏目:
综述
出版日期:
2024-06-20

文章信息/Info

Title:
Research progress in TACE-based combination therapy for primary hepatocellular carcinoma
作者:
肖正芳;  郑游冰;  邓飞燕;  郑思茜;  孙宏伟;  刘妍妍;  陆骊工
Author(s):
XIAO Zhengfang;  ZHENG Youbing;  DENG Feiyan;  ZHENG Siqian;  SUN Hongwei;  LIU Yanyan;  LU Ligong.
Affiliated Zhuhai Hospital of Jinan University （Zhuhai Municipal People’s Hospital）， Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment， Zhuhai， Guangdong Province 519000， China
关键词:
【关键词】 肝细胞癌;  肝动脉化疗栓塞;  灌注化疗;  靶向治疗;  免疫治疗;  联合治疗
文献标志码:
A
摘要:
【摘要】 肝癌是常见且恶性程度高的癌症之一，其中90%为肝细胞癌，对人类健康构成严重威胁。由于早期肝癌无特异性表现，大部分确诊时已处于中晚期，错过了最佳的根治治疗时机。关于中晚期原发性肝细胞癌治疗的探索从未停歇。近年来，经动脉化疗栓塞术（transarterial chemoembolization，TACE）已被纳入原发性肝细胞癌的标准治疗方案中。随着多学科综合治疗的推进，各种减轻肝细胞癌负荷的治疗方案已经广泛应用于临床中，如肝动脉灌注化疗（hepatic artery infusion chemotherapy，HAIC）、靶向治疗和免疫治疗等与TACE的联用，提高了肝癌患者的总生存率。本文重点介绍原发性肝细胞癌研究中，TACE与其他疗法的联用在降低肿瘤负荷、提高患者生存率方面的进展，并总结联合治疗中需要进行更深入研究的关键问题。

参考文献/References:

 

［1］ Sung H， Ferlay J， Siegel RL， et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin， 2021， 71： 209- 249.

［2］ Rinaldi L， Guarino M， Perrella A， et al. Role of liver stiffness measurement in predicting HCC occurrence in direct- acting antivirals setting： a real- life experience［J］. Dig Dis Sci， 2019， 64： 3013- 3019.

［3］ Schweitzer A， Horn J， Mikolajczyk RT， et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection： a systematic review of data published between 1965 and 2013［J］. Lancet， 2015， 386： 1546- 1555.

［4］ Bruix J， Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma［J］. Hepatology， 2002， 35： 519- 524.

［5］ Lin SM. Local ablation for hepatocellular carcinoma in Taiwan［J］. Liver Cancer， 2013， 2： 73- 83.

［6］ Marrero JA， Kulik LM， Sirlin CB， et al. Diagnosis， staging， and management of hepatocellular carcinoma： 2018 practice guidance by the American association for the study of liver diseases［J］. Hepatology， 2018， 68： 723- 750.

［7］ Chang Y，Jeong SW，Young Jang J，et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］. Int J Mol Sci， 2020， 21： 8165.

［8］ 丁晓毅，王 征，石 洁，等． 中国肝癌多学科综合治疗专家共识［J］． 临床肝胆病杂志， 2021， 37：278- 285．

［9］ Guo W，Gao J，Zhuang W，et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma： a propensity score- matching cohort study［J］. JGH Open， 2020， 4： 477- 483.

［10］ Kim HY， Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma： past， present， and future［J］. Liver Cancer， 2014， 3： 9- 17.

［11］ Kudo M， Ueshima K， Ikeda M， et al. Randomised， multicentre prospective trial of transarterial chemoembolisation（TACE） plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma： TACTICS trial［J］. Gut， 2020， 69： 1492- 1501.

［12］ Lencioni R， de Baere T， Soulen MC， et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma： a systematic review of efficacy and safety data［J］. Hepatology， 2016， 64： 106- 116.

［13］ Cucchetti A， Piscaglia F， Cescon M， et al. Cost- effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma［J］. J Hepatol， 2013， 59： 300- 307.

［14］ Golfieri R，Giampalma E，Renzulli M，et al. Randomised controlled trial of doxorubicin- eluting beads vs conventional chemoembo-lisation for hepatocellular carcinoma［J］. Br J Cancer， 2014， 111： 255- 264.

［15］ Facciorusso A， Mariani L， Sposito C， et al. Drug- eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2016， 31： 645- 653.

［16］ Irie T，Kuramochi M，Kamoshida T，et al. Selective balloon- occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules： retrospective comparison with conventional super- selective TACE［J］. Hepatol Res， 2016， 46： 209- 214.

［17］ Llovet JM， Real MI， Montana X， et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma： a randomised controlled trial［J］. Lancet， 2002， 359： 1734- 1739.

［18］ Orlacchio A， Chegai F， Merolla S， et al. Downstaging disease in patients with hepatocellular carcinoma outside up- to- seven criteria： strategies using degradable starch microspheres transcatheter arterial chemo- embolization［J］. World J Hepatol， 2015， 7： 1694- 1700.

［19］ Kudo M，Matsui O，Izumi N，et al. JSH consensus- based clinical practice guidelines for the management of hepatocellular carcinoma： 2014 update by the liver cancer study group of Japan［J］. Liver Cancer， 2014， 3： 458- 468.

［20］ Lyu N，Kong YN，Mu LW，et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma［J］. J Hepatol， 2018， 69： 60- 69.

［21］ Ogasawara S， Ooka Y， Itokawa N， et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma： a multicenter retrospective study in Japan［J］. Invest New Drugs， 2020， 38： 172- 180.

［22］ Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma［J］. World J Gastroenterol， 2015， 21： 3843- 3849.

［23］ Chen CT，Liu TH，Shao YY，et al. Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma［J］. Int J Mol Sci， 2021， 22： 12880.

［24］ Zhao X， Sun X， Jing J， et al. Safety study of FOLFOX- HAIC in relieving bed restriction［J］. J Interv Med， 2021， 4： 203- 207.

［25］ Gao S，Zhang PJ，Guo JH，et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients［J］. World J Gastroenterol， 2015， 21： 10443- 10452.

［26］ Liu BJ，Gao S，Zhu X，et al. Combination therapy of chemoem-bolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone： a propensity score- matched analysis［J］. Biomed Res Int， 2021， 2021： 6670367.

［27］ Kodama K， Kawaoka T， Aikata H， et al. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status［J］. J Gastroenterol Hepatol， 2018， 33： 1780- 1786.

［28］ Radu P， Dufour JF. Changing TACTICS in intermediate HCC： TACE plus sorafenib［J］. Gut， 2020， 69： 1374- 1376.

［29］ Hulin AN，Stocco J，Bouattour M. Clinical pharmacokinetics and pharmacodynamics of transarterial chemoembolization and targeted therapies in hepatocellular carcinoma［J］. Clin Pharmacokinet， 2019， 58： 983- 1014.

［30］ Hatanaka T， Yata Y， Naganuma A， et al. Treatment strategy for intermediate- stage hepatocellular carcinoma： transarterial chemo- embolization， systemic therapy， and conversion therapy［J］. Cancers（Basel）， 2023， 15： 1798.

［31］ Peng Z，Fan W，Zhu B，et al. Lenvatinib combined with transar-terial chemoembolization as first- line treatment for advanced hepatocellular carcinoma： a phase Ⅲ， randomized clinical trial （LAUNCH）［J］. J Clin Oncol， 2023， 41： 117- 127.

［32］ Cai R，Song R，Pang P，et al. Transcatheter arterial chemoembo-lization plus sorafenib versus transcatheter arterial chemoembo-lization alone to treat advanced hepatocellular carcinoma： a meta- analysis［J］. BMC Cancer， 2017， 17： 714.

［33］ Kudo M， Kawamura Y， Hasegawa K， et al. Management of hepatocellular carcinoma in Japan： JSH consensus statements and recommendations 2021 update［J］. Liver Cancer， 2021， 10： 181- 223.

［34］ Okusaka TKI，Ikeda M. Immunotherapy for hepatocellular carcinoma： current status and future perspectives［J］. ESMO Open， 2018， 3： e000455.

［35］ Lawal G， Xiao Y， Rahnemai- Azar AA， et al. The immunology of hepatocellular carcinoma［J］. Vaccines （Basel）， 2021， 9： 1184.

［36］ Xue J， Ni H， Wang F， et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Interv Med， 2021， 4： 105- 113.

［37］ 王 曦，冯 苏，李 红，等． 免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展［J］． 介入放射学杂志， 2023， 32：90- 93．

［38］ El- Khoueiry AB， Sangro B， Yau T， et al. Nivolumab in patients with advanced hepatocellular carcinoma（CheckMate 040）： an open- label， non- comparative， phase 1/2 dose escalation and expansion trial［J］. Lancet， 2017， 389： 2492- 2502.

［39］ Hato T， Zhu AX， Duda DG. Rationally combining anti- VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma［J］. Immunotherapy， 2016， 8： 299- 313.

［40］ Khan KA， Kerbel RS. Improving immunotherapy outcomes with anti- angiogenic treatments and vice versa［J］. Nat Rev Clin Oncol， 2018， 15： 310- 324.

［41］ Zhang JX，Chen P，Liu S，et al. Safety and efficacy of transarterial chemoembolization and immune checkpoint inhibition with camre- lizumab for treatment of unresectable hepatocellular carcinoma［J］. J Hepatocell Carcinoma， 2022， 9： 265- 272.

［42］ Vogel A， Cervantes A， Chau I， et al. Hepatocellular carcinoma： ESMO Clinical Practice Guidelines for diagnosis， treatment and follow- up［J］. Ann Oncol， 2018， 29： iv238- iv255.

［43］ Finn RS， Qin S， Ikeda M， et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med， 2020， 382： 1894- 1905.

［44］ Ren Z，Xu J，Bai Y，et al. Sintilimab plus a bevacizumab biosimilar（IBI305） versus sorafenib in unresectable hepatocellular carcinoma （ORIENT- 32）： a randomised， open- label， phase 2- 3 study［J］. Lancet Oncol， 2021， 22： 977- 990.

［45］ Kelley RK， Rimassa L， Cheng AL， et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma（COSMIC- 312）： a multicentre， open- label， randomised， phase 3 trial［J］. Lancet Oncol， 2022， 23： 995- 1008.

［46］ Wu JY，Yin ZY，Bai YN，et al. Lenvatinib combined with anti- PD- 1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma： a multicenter retrospective study［J］. J Hepatocell Carcinoma， 2021， 8： 1233- 1240.

［47］ Han Y，Cao G，Sun B，et al. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma： a real- world study［J］. BMC Gastroenterol， 2021， 21： 393.

［48］ 中华人民共和国国家卫生健康委员会．原发性肝癌诊疗指南（2022年版）［J］． 肿瘤综合治疗电子杂志， 2022， 8：16- 53．

［49］ Reig M，Forner A，Rimola J，et al. BCLC strategy for prognosis prediction and treatment recommendation： the 2022 update［J］. J Hepatol， 2022， 76： 681- 693.

［50］ Yuan Y，He W，Yang Z，et al. TACE- HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus： a propensity score matching study［J］. Int J Surg， 2023， 109： 1222- 1230.

［51］ 李 灵， 贺 剑， 谢义星，等. TACE- HAIC- 靶向-免疫四联治疗中晚期肝细胞癌的回顾性对照研究［J］. 中华肝脏病杂志， 2022， 30： 939- 946.

 

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(06):177.
[2]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(06):333.
[4]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].journal interventional radiology,2012,(06):348.
[5]卢丽琴,陈方宏,袁建华,等.晚期肝癌伴门脉癌栓的介入治疗[J].介入放射学杂志,1996,(03):136.
[6]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(06):206.
[7]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合ＣＴ引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
　,,et al.Ｓｅｑｕｅｎｔｉａｌ ｔｒｅａｔｍｅｎｔ ｗｉｔｈ ＴＡＣＥ ａｎｄ ＣＴｇｕｉｄｅｄ ＲＦＡ ｆｏｒ ｓｍａｌｌ ａｎｄ ｍｏｄｅｒａｔｅ ｓｉｚｅｄ ＨＣＣ [J].journal interventional radiology,2012,(06):301.
[8]帕哈尔丁·白克热,杨树法,黄伍奎,等.肝动脉化疗栓塞联合射频消融术治疗３０例原发性大肝癌的疗效评价[J].介入放射学杂志,2012,(04):322.
　,,et al.ＴＡＣＥ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ｒａｄｉｏｆｒｅｑｕｅｎｃｙ ａｂｌａｔｉｏｎ ｆｏｒ ｍａｓｓｉｖｅ ｐｒｉｍａｒｙ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ａ ｃｌｉｎｉｃａｌ ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ [J].journal interventional radiology,2012,(06):322.
[9]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(06):469.
[10]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(06):974.
[11]刘 丽,钟嘉明,陈晓霞,等.肝动脉化疗栓塞术联合自体DC CIK细胞治疗BCLC C期肝癌的随机对照研究[J].介入放射学杂志,2015,(05):434.
　LIU Li,ZHONG Jia ming,CHEN Xiao xia,et al.Transarterial chemoembolization combined with autologous DC CIK cells for the treatment of hepatocellular carcinoma of BCLC C stage： a randomized controlled study[J].journal interventional radiology,2015,(06):434.
[12]黄文薮,蔡明岳,曾昭吝,等.TACE联合125I放射性粒子植入治疗肝细胞癌门静脉癌栓[J].介入放射学杂志,2015,(06):488.
　HUANG Wen- sou,CAI Ming- yue,ZENG Zhao- lin,et al.Transarterial chemoembolization combined with CT- guided 125I seed implantation for the treatment of hepatocellular carcinoma associated with portal vein tumor thrombus[J].journal interventional radiology,2015,(06):488.
[13]刘德鑫,王 伟,李新丰,等.肝动脉化疗栓塞联合粒子植入治疗肝癌自发性破裂出血的临床研究[J].介入放射学杂志,2015,(11):999.
　LIU De- xin,WANG Wei,LI Xin- feng,et al.TACE combined with radioactive seed implantation for the treatment of abdominal hemorrhage due to spontaneous rupture of primary hepatocellular carcinoma： a clinical study[J].journal interventional radiology,2015,(06):999.
[14]刘 毅,卓 琳,朱 蓓,等.肝动脉化疗栓塞联合经皮消融治疗肝细胞癌疗效的meta分析 [J].介入放射学杂志,2017,(09):830.
　LIU Yi,ZHUO Lin,ZHU Bei,et al.Transcatheter arterial chemoembolization in combination with percutaneous ablation therapy for the treatment of hepatocellular carcinoma： a meta- analysis[J].journal interventional radiology,2017,(06):830.
[15]陆 阳,姜永能,万 程,等.阿帕替尼联合TACE治疗中晚期肝细胞癌的疗效研究[J].介入放射学杂志,2019,28(02):162.
　LU Yang,JIANG Yongneng,WAN Cheng,et al.Curative effect of apatinib combined with TACE for advanced hepatocellular carcinoma[J].journal interventional radiology,2019,28(06):162.
[16]苏 珂,徐尧阳,郭 露,等.肝动脉化疗栓塞联合卡瑞利珠单抗治疗中晚期肝细胞癌的疗效分析[J].介入放射学杂志,2022,31(09):865.
　SU Ke,XU Yaoyang,GUO Lu,et al.Hepatic arterial chemoembolization combined with camrelizumab for the treatment of mid-to-advanced hepatocellular carcinoma： analysis of its curative efficacy[J].journal interventional radiology,2022,31(06):865.
[17]刘晓侃,洪 鑫,许若男,等.CT影像组学联合血清炎症参数预测肝癌根治术后辅助TACE的早期复发[J].介入放射学杂志,2023,32(11):1075.
　LIU Xiaokan,HONG Xin,XU Ruonan,et al.CT radiomics combined with serum inflammatory parameters in predicting early recurrence of hepatocellular carcinoma after radical resection followed by adjuvant TACE[J].journal interventional radiology,2023,32(06):1075.

备注/Memo

备注/Memo:
（收稿日期：2023- 05- 31）

（本文编辑：新 宇）
更新日期/Last Update: 2024-06-20